Key Highlights
- Futura Medical plc (LSE:FUM) was shown up 10.00% on 24 September 2026, putting the stock among the strongest movers in the session.
- The company has an established commercial product in Eroxon, its topical treatment for erectile dysfunction, alongside two development opportunities: Eroxon Intense and WSD4000.
- Eroxon is now commercially available in 27 countries, including the US, Mexico, much of Europe and several Middle Eastern markets.
- Eroxon Intense is being developed as an enhanced formulation aimed at consumers seeking a stronger and faster sensory effect, with first market launches targeted for early 2027.
- Futura's March 2026 home-user study involving 223 men produced positive results for both Eroxon and Eroxon Intense.
- WSD4000 is Futura's female sexual-health development programme and has generated encouraging early feasibility data, supporting further clinical development.
- The company reported its interim results on 1 September 2026, making the latest financial and operational update an important reference point for investors.
- Investors are watching commercial sales growth, regulatory progress for Eroxon Intense, partner expansion, WSD4000 development and the company's cash position.
Why Is Futura Medical (LSE:FUM) in Focus on 24 September 2026?
Futura Medical has attracted renewed attention after LSE:FUM gained 10.00% on 24 September 2026.
The company is different from a conventional pharmaceutical developer because it already has a commercially available product in Eroxon while simultaneously developing additional products that could broaden its addressable market.
Eroxon is already available across multiple international markets, while Eroxon Intense and WSD4000 provide additional potential growth avenues.
This creates a combination of commercial revenue, product extensions and development-stage opportunities that investors are monitoring as Futura moves through 2026.
Why Is Eroxon Central to the LSE:FUM Story?
Eroxon remains Futura's lead commercial product.
It is a topical gel for erectile dysfunction that works through a physical, evaporative mechanism rather than a conventional pharmaceutical mechanism. Futura says Eroxon is clinically proven and available without prescription in the US and Europe.
The product has already expanded beyond its original European markets and is now available in 27 countries.
For LSE:FUM, this international footprint is important because future growth depends increasingly on consumer adoption, repeat purchases, Marketing execution and commercial-partner performance rather than solely on regulatory approval.
Why Is the US Market Important for Futura Medical?
The US is particularly important because it is one of the world's largest markets for erectile-dysfunction treatments.
Eroxon launched in the US in 2024 and is available through leading retailers. Futura has also been developing its commercial relationships and intellectual-property position in the country.
The company has previously disclosed that a US continuation Patent granted in March 2026 was expected to trigger a US$2.5 million milestone payment under its licensing arrangement, with discussions concerning the interpretation and timing of that payment.
The US therefore remains an important area for both commercial expansion and intellectual-property protection.
What Is Eroxon Intense and Why Is It Important?
Eroxon Intense is designed as an enhanced version of the existing Eroxon product.
Futura describes it as an additional treatment option intended for men who may prefer a stronger and faster sensory action.
A 2026 home-user test involving 223 men under 60, predominantly with mild-to-moderate erectile dysfunction, produced positive results for both products. Futura reported satisfaction with erection hardness in 70% of sexual encounters using Eroxon and 71% using Eroxon Intense, while erections lasted long enough for intercourse in 84% and 85% of encounters respectively.
The company also reported statistically stronger sensory intensity during the first two minutes with Eroxon Intense.
Futura is targeting initial market launches for the enhanced formulation from early 2027, subject to the required regulatory and commercial steps.
Why Could Eroxon Intense Become a Catalyst for LSE:FUM?
Eroxon Intense potentially gives Futura an opportunity to expand the existing Eroxon Franchise without having to establish an entirely new therapeutic category.
The company is working on supply-chain preparation, regulatory requirements and Brand positioning.
The key areas investors will monitor include:
- Regulatory clearance
- Manufacturing readiness
- Commercial-partner agreements
- Pricing
- Consumer uptake
- Repeat purchases
- Geographic expansion
- Marketing expenditure
Successful introduction could provide an additional product within Futura's existing commercial infrastructure.
What Is WSD4000 and Why Are Investors Watching It?
WSD4000 is Futura's development programme targeting female sexual health.
The programme is based around topical gels designed for symptoms associated with impaired sexual response and function in women.
Futura's early feasibility study involved 11 participants and produced encouraging results. The company reported improvements across several domains of the Female Sexual Function Index, while the product was generally well tolerated in the study.
The company subsequently planned further development work, including home-user and controlled studies, with the longer-term objective of progressing toward a Phase 3 programme.
This gives LSE:FUM exposure to a potentially broader healthcare market beyond erectile dysfunction.
Why Is WSD4000 Strategically Important?
The strategic attraction of WSD4000 is that Futura is attempting to develop a portfolio rather than depend entirely on Eroxon.
The company says its development strategy is designed around potentially using one Phase 3 clinical programme to support multiple topical-gel variants aimed at different consumer segments.
Futura has also reported positive consumer research around the WSD4000 concept.
However, the programme remains developmental. Investors will therefore need to distinguish between encouraging early-stage data and eventual regulatory approval, commercialisation and Revenue generation.
What Did Futura Report Financially in 2026?
Futura's financial position remains an important consideration because the company is simultaneously commercialising Eroxon and funding development programmes.
The company's 2025 Annual Report highlighted the importance of milestone receipts and commercial revenues in extending its cash runway. It also reported that the company had delivered several of its stated 2026 objectives, including positive Eroxon Intense home-user-test results and progress on intellectual-property protection.
The company subsequently published its interim results for the six months ended 30 June 2026 on 1 September 2026.
For LSE:FUM, investors are likely to focus on cash resources, commercial revenue, milestone income, development expenditure and funding requirements.
What Are Investors Watching Next for LSE:FUM?
The main potential catalysts include:
- Eroxon sales growth
- Expansion into additional international markets
- US commercial performance
- Eroxon Intense regulatory progress
- Early 2027 Eroxon Intense launch preparations
- New commercial partnerships
- WSD4000 development
- Further clinical data
- Potential licensing or milestone income
- Cash runway and funding requirements
The September corporate-information flow also shows several Shareholder and regulatory filings during the month, although these should not automatically be interpreted as operating catalysts.
What Does the 10.00% Rise Mean for LSE:FUM?
The 10.00% gain shown for LSE:FUM on 24 September 2026 places Futura Medical among the stronger movers highlighted in the session.
There is no single newly identified operating announcement on 24 September that can definitively explain the entire day's percentage move. The broader backdrop includes Futura's established Eroxon commercial platform, ongoing international expansion, Eroxon Intense development and WSD4000 progress.
The market is therefore likely to remain focused on whether these initiatives can translate into higher recurring commercial revenues and additional product-based value.
What Could Keep Futura Medical in Focus?
Futura enters an important period in which the existing Eroxon franchise and newer development programmes are progressing simultaneously.
Eroxon provides the current commercial foundation, while Eroxon Intense could extend that franchise from 2027. WSD4000 represents a longer-term opportunity in female sexual health.
The company's ability to convert its international distribution network into stronger sales, secure further commercial partners and progress its pipeline while managing cash requirements will remain central to the LSE:FUM story.
For investors watching the 10.00% rise on 24 September, the major themes are therefore Eroxon commercial momentum, Eroxon Intense regulatory progress, WSD4000 clinical development and the company's funding position.






Please wait processing your request...